Free Newsletter
CMO to scale up bio anti-cancer drug
Amsterdam-based SynCo Bio Partners has expanded its reach to Japan, where it will manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company.
The contract manufacturer will first consultant with the unnamed drug maker on in-house process development. The developed process will then be transferred to SynCo's Amsterdam facility and scaled-up, prior to GMP manufacturing of a live, biotherapeutic-based anticancer drug for Phase I clinical trials. The scale-up effort will include fermentation, formulation and aseptic filling.
SynCo announced a month ago a deal to produce Versartis's lead candidate, a GLP-1 analog for monthly dosing to treat type 2 diabetes. As with the Japanese deal, the CMO is further developing the existing production process. It is also optimizing the manufacturing process to increase yields for cGMP production.
- here's the SynCo release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: